The King of Ozempic Is Scared as Hell
Now that Novo Nordisk is the world’s weight-loss juggernaut, will it have to betray its first patients—type 1 diabetics?
pharmaphorum8d
Novo Nordisk once-weekly insulin clears first phase 3 test
Novo Nordisk is also pairing the long-acting insulin with its once-weekly GLP-1 agonist semaglutide in the COMBINE trials programme, which is due to complete in 2024, is also working on a glucose ...
Novo Nordisk, Valo Health Expand Drug Discovery and Development Pact
The deal expands a deal to discover and develop treatments for obesity, type 2 diabetes and cardiovascular disease using ...
Novo Nordisk Pushes FDA To Exclude Compounding For Its Early-Generation Diabetes Drug
Novo Nordisk petitions the FDA to exclude liraglutide from the 503B Bulks List, citing safety risks, lack of clinical need, ...
Hosted on MSN3d
Trump Wants Greenland. Why That Could Be Bad News for Novo Nordisk Stock.
President-elect Donald Trump has asserted that, due to national security interests, he intends to acquire Greenland and ...
FiercePharma13d
Novo asks FDA to restrict Victoza compounding amid GLP-1 outsourcing row
In a citizen petition posted by the FDA this week, Novo urged the regulator to restrict the ability of compounding pharmacies ...
Nasdaq8d
Novo Nordisk upgraded to Buy from Neutral at UBS, as CagriSema selloff overdone
UBS analyst upgraded Novo Nordisk (NVO) to Buy from Neutral with ... efficacy treatment that could still show differentiation in type 2 diabetes. UBS is a buyer of weakness and says shares are ...
CNN27d
An experimental drug drove people to lose 23% of their body weight. It’s still seen as a disappointment
Since Ozempic blasted onto the stage in 2017 with its approval for type 2 diabetes, drugmakers Novo Nordisk and Eli Lilly ... as GLP-1 that’s important for insulin secretion, digestion and ...